M Heslinga1, Iam Van Den Oever1, D L Jonker2, E N Griep2, Hrm Griep-Wentink2, Y M Smulders3, W F Lems1,4, M Boers4,5, A E Voskuyl4, Mjl Peters3, D Van Schaardenburg1,5, M T Nurmohamed1,4,6. 1. Amsterdam Rheumatology and Immunology Center/Reade , Amsterdam , The Netherlands. 2. Department of Rheumatology, Antonius Hospital , Sneek , The Netherlands. 3. Department of Internal Medicine, VU University Medical Center , Amsterdam , The Netherlands. 4. Amsterdam Rheumatology and Immunology Center/VU University Medical Center , Amsterdam , The Netherlands. 5. Department of Epidemiology and Biostatistics, VU University Medical Center , Amsterdam , The Netherlands. 6. Amsterdam Rheumatology and Immunology Center/AMC , Amsterdam , The Netherlands.
Abstract
Objective: In 2011, we started to offer cardiovascular (CV) risk screening to rheumatoid arthritis (RA) patients with a high CV risk. After 1 year, we assessed whether patients labelled as high CV risk had started preventive treatment when indicated, and whether the CV risk score had changed. Methods: CV risk screening was performed in both a large outpatient rheumatology clinic and a general hospital in the Netherlands, and the general practitioner or the internist was informed about the results of the CV screening, including specific advice on the initiation or adjustment of cardiopreventive drugs. National guidelines were used to assess how many patients were eligible for preventive treatment. After 1 year, CV risk, lifestyle, and treatment were re-evaluated. Patients with a history of CV disease at baseline or who experienced a CV event during follow-up were excluded from the analyses. Results: A high 10 year CV risk (> 20%) was present in 58%, and 55% had an indication for anti-hypertensives, statins, or both. At follow-up, cardiopreventive drug treatment had been started or adjusted in only one-third of patients with an indication for treatment. After screening, 42% of patients reported having changed their lifestyle, through more exercise (24%), diet adaption (20%), and weight loss (11%). Conclusion: Despite clear guidelines to improve CV risk, the results of a programme comprising active screening, targeted advice, and referral to the general practitioner or internist prove that primary prevention remains a major challenge in high-risk RA patients.
Objective: In 2011, we started to offer cardiovascular (CV) risk screening to rheumatoid arthritis (RA) patients with a high CV risk. After 1 year, we assessed whether patients labelled as high CV risk had started preventive treatment when indicated, and whether the CV risk score had changed. Methods: CV risk screening was performed in both a large outpatient rheumatology clinic and a general hospital in the Netherlands, and the general practitioner or the internist was informed about the results of the CV screening, including specific advice on the initiation or adjustment of cardiopreventive drugs. National guidelines were used to assess how many patients were eligible for preventive treatment. After 1 year, CV risk, lifestyle, and treatment were re-evaluated. Patients with a history of CV disease at baseline or who experienced a CV event during follow-up were excluded from the analyses. Results: A high 10 year CV risk (> 20%) was present in 58%, and 55% had an indication for anti-hypertensives, statins, or both. At follow-up, cardiopreventive drug treatment had been started or adjusted in only one-third of patients with an indication for treatment. After screening, 42% of patients reported having changed their lifestyle, through more exercise (24%), diet adaption (20%), and weight loss (11%). Conclusion: Despite clear guidelines to improve CV risk, the results of a programme comprising active screening, targeted advice, and referral to the general practitioner or internist prove that primary prevention remains a major challenge in high-risk RApatients.
Authors: M Sobejana; J van den Hoek; G S Metsios; G D Kitas; M van der Leeden; S Verberne; H T Jorstad; M Pijnappels; W F Lems; M T Nurmohamed; M van der Esch Journal: Clin Rheumatol Date: 2022-08-25 Impact factor: 3.650
Authors: Katelynn M Wilton; Sara J Achenbach; John M Davis; Elena Myasoedova; Eric L Matteson; Cynthia S Crowson Journal: J Rheumatol Date: 2021-01-15 Impact factor: 5.346
Authors: Jorge Enrique Machado-Alba; Manuel E Machado-Duque; Andres Gaviria-Mendoza; Juan Manuel Reyes; Natalia Castaño Gamboa Journal: Clin Rheumatol Date: 2020-09-30 Impact factor: 2.980